Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma

Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma

Show other versions (1)

The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically with the introduction of targeted therapies including sunitinib, sorafenib, and temsirolimus. Because patients with conventional clear cell histology account for 75- 80% of all patients with RCC, there has been little ac...

Full description

Bibliographic Details
Main Authors:	Daniel Y.C. Heng, Ronald M. Bukowski
Format:	Article
Language:	English
Published:	PAGEPress Publications 2011-12-01
Series:	Oncology Reviews
Subjects:	Renal cell cancer - Non-clear cell - Papillary - Chromophobe - Collecting duct - Sunitinib - Sorafenib - Temsirolimus
Online Access:	http://www.oncologyreviews.org/index.php/or/article/view/152

Similar Items

Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)

Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer
by: Dimitrios Zardavas, et al.
Published: (2011-01-01)

The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
by: Andrea Marchetti, et al.
Published: (2021-06-01)

Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy
by: In Hee Lee, et al.
Published: (2020-01-01)

Prognostic markers and new, innovative treatments in renal cell carcinoma
by: Secasan Ciprian
Published: (2009-01-01)

Research Progress on Molecular Genetic Alterations of Renal Cell Carcinoma
by: WANG Jie, et al.
Published: (2018-04-01)

DNA methylation profiling reveals new potential subtype-specific gene markers for early-stage renal cell carcinoma in Caucasian population
by: Agustriawan, D., et al.
Published: (2022)

Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis
by: Vivek Agarwala, et al.
Published: (2018-01-01)

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
by: Maroto P, et al.
Published: (2017-09-01)

Metastatic renal cell carcinoma: A guide to therapy based on current evidence
by: Choueiri Toni
Published: (2009-01-01)

Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
by: Ana Elena Martín-Aguilar, et al.
Published: (2021-01-01)

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
by: Radek Lakomy, et al.
Published: (2017-12-01)

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
by: Wen Cai, et al.
Published: (2017-08-01)

Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies
by: Yi Xiao, et al.
Published: (2019-07-01)

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
by: Chenchen Feng, et al.
Published: (2021-09-01)

Immunosuppressive peculiarities of stromal cells of various kidney tumor types
by: O. V. Kovaleva, et al.
Published: (2020-07-01)

Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis
by: Francesca Giunchi, et al.
Published: (2020-02-01)

Prevalence of Different Subtypes of Renal Cell Carcinoma among Patients who have Undergone Nephrectomy; Statistics of a Referral Medical Center in Iran
by: Zahra Mohajer, et al.
Published: (2021-03-01)

Role of presurgical targeted molecular therapy in renal cell carcinoma with an inferior vena cava tumor thrombus
by: Peng C, et al.
Published: (2018-04-01)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
by: Huan Deng, et al.
Published: (2019-06-01)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
by: Nanna Bæk Møller, et al.
Published: (2019-09-01)

A rare case of synchronous association of chromophobe renal cell carcinoma with urothelial carcinoma of urinary bladder
by: A. Chaurasia, et al.
Published: (2017-06-01)

Pazopanib in the treatment of advanced renal cell carcinoma
by: M. I. Volkova, et al.
Published: (2018-11-01)

Chromophobe Renal Cell Carcinoma.
by: Jyotsna Vijaykumar Wader, et al.
Published: (2013-04-01)

NEW CAPACITIES OF TARGETED THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
by: B. Ya. Alekseyev, et al.
Published: (2014-08-01)

Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma treated with cabozantinib and nivolumab
by: Carlos Eduardo Salazar-Mejía, et al.
Published: (2020-12-01)

Imprint cytology of the chromophobe renal cell carcinoma: Correlation with the histological and ultrastructural features
by: Wonae Lee
Published: (2011-01-01)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
by: Shibasaki, Noboru
Published: (2016)

Spindle cell renal cell carcinoma diagnosed after sunitinib treatment for chromophobe renal cell carcinoma
by: Ruriko Honda‐Takinami, et al.
Published: (2020-03-01)

Chromophobe renal cell carcinoma in an 18-year-old female
by: I. Saguem, et al.
Published: (2016-09-01)

The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature
by: Bi J, et al.
Published: (2017-07-01)

NEW CAPACITIES OF TARGETED THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
by: B. Ya. Alekseyev, et al.
Published: (2014-08-01)

Multicentric papillary and chromophobe renal cell carcinomas in a patient with autosomal dominant polycystic kidney disease: Report of a rare case
by: Nibedita Sahoo, et al.
Published: (2017-01-01)

Abstract P-37: Ultrastructural Differential-Diagnostic Criteria for Renal Oncocytoma and Chromophobe Renal Cell Carcinoma
by: Elena Smirnova, et al.
Published: (2019-06-01)

THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
by: N. Bhojani, et al.
Published: (2014-08-01)

THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
by: N. Bhojani, et al.
Published: (2014-08-01)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
by: Magdalena Rausch, et al.
Published: (2021-06-01)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
by: Yuang Wei, et al.
Published: (2021-07-01)

Chromophobe renal cell carcinoma: A report of two cases with unusual histological features
by: Marie Therese Manipadam, et al.
Published: (2008-01-01)

Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma
by: Shuping Wei, et al.
Published: (2019-12-01)